MyFinsight

HomeBlogAboutContact

MyFinsight

Making company financials insightful for everyone

Quick Links

  • About
  • Blog
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

|||

For the quarter ending 2025-09-30, STOK had -$18,152K decrease in cash & cash equivalents over the period. -$30,498K in free cash flow.

Cash Flow Overview

Change in Cash
-$18,152K
Free Cash flow
-$30,498K

Unit: Thousand (K) dollars (except for numbers of shares and EPS)
Cash Flow
2025-09-30
2025-06-30
Net income (loss)
-38,348 89,397
Depreciation
442 923
Amortization and accretion of marketable securities
-615 33
Stock-based compensation
8,039 14,351
Impairment of right of use asset
696 -
Loss on disposal of property and equipment
8 -
Reduction in the carrying amount of right of use assets
547 1,211
Accounts receivable
7,580 -
Prepaid expenses and other current assets
-5,640 6,405
Accounts payable, accrued liabilities and lease liabilities
4,881 7,506
Deferred revenue
-4,060 -611
Net cash provided by (used in) operating activities
-30,366 106,405
Purchases of marketable securities
23,925 200,569
Purchases of property and equipment
132 306
Sales of marketable securities
33,151 66,030
Net cash used in investing activities
9,094 -134,845
Proceeds from employee stock purchase plan
632 370
Proceeds from issuance of common stock upon exercise of stock options
2,488 1,558
Net cash provided by financing activities
3,120 1,928
Net decrease in cash, cash equivalents and restricted cash
-18,152 -26,512
Cash and cash equivalents at beginning of period
128,779 -
Cash and cash equivalents at end of period
84,115 -
Unit: Thousand (K) dollars

Time Plot

Show the time plot by selecting a row from the table.

Stoke Therapeutics, Inc. (STOK)

Stoke Therapeutics, Inc. (STOK)